NasdaqCM - Delayed Quote USD

GRI Bio, Inc. (GRI)

0.4374 -0.0095 (-2.13%)
At close: April 24 at 4:00 PM EDT
0.4455 +0.01 (+1.85%)
After hours: April 24 at 6:42 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. W. Marc Hertz Ph.D. Co-Founder, CEO, President & Director 842.01k -- 1971
Ms. Leanne M. Kelly CFO & Corporate Secretary 550.93k -- 1977
Dr. Vipin Kumar Chaturvedi Ph.D. Co-Founder & Chief Scientific Officer -- -- 1960
Dr. Albert Agro Ph.d. Chief Medical Officer -- -- 1965

GRI Bio, Inc.

2223 Avenida de la Playa
Suite 208
LA Jolla, CA 92037
United States
619 400 1170 https://www.gribio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
4

Description

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Corporate Governance

GRI Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 13, 2024 - May 17, 2024
GRI Bio, Inc. Earnings Call

Related Tickers

PBLA Panbela Therapeutics, Inc.
0.4101
-2.36%
 
LUMO Lumos Pharma, Inc.
2.7950
-0.18%
 
CING Cingulate Inc.
0.8700
-0.99%
 
BDRX Biodexa Pharmaceuticals Plc
0.7499
-3.87%
 
ENSC Ensysce Biosciences, Inc.
0.5586
-1.48%
 
THAR Tharimmune, Inc.
0.3720
-1.85%
 
ELAB Elevai Labs, Inc.
0.6040
+1.51%
 
REVB Revelation Biosciences, Inc.
2.0900
+0.97%
 
NBY NovaBay Pharmaceuticals, Inc.
0.0773
+0.39%
 
ZVSA ZyVersa Therapeutics, Inc.
0.6100
+6.64%